EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Informatics and Artificial Intelligence–Guided Assessment of the Regulatory and Translational Research Landscape of First-in-Class Oncology Drugs in the United States, 2018-2022

Jay G Ronquillo iD, Brett South, Prakash Naik, Rominder Singh iD, Magdia De Jesus, Stephen J Watt, Aida Habtezion

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci.24.00087 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Jay G Ronquillo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Worldwide Medical and Safety, Pfizer Inc, New York, NY. Hauptthemen laut MEDLINE: Artificial Intelligence, Translational Research, Biomedical, United States Food and Drug Administration, Drug Approval. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Cancer drug development remains a critical but challenging process that affects millions of patients and their families. Using biomedical informatics and artificial intelligence (AI) approaches, we assessed the regulatory and translational research landscape defining successful first-in-class drugs for patients with cancer. METHODS This is a retrospective observational study of all novel first-in-class drugs approved by the US Food and Drug Administration (FDA) from 2018 to 2022, stratified by cancer versus noncancer drugs. A biomedical informatics pipeline leveraging interoperability standards and ChatGPT performed integration and analysis of public databases provided by the FDA, National Institutes of Health, and WHO. RESULTS Between 2018 and 2022, the FDA approved a total of 247 novel drugs, of which 107 (43.3%) were first-in-class drugs involving a new biologic target. Of these first-in-class drugs, 30 (28%) treatments were indicated for patients with cancer, including 19 (63.3%) for solid tumors and the remaining 11 (36.7%) for hematologic cancers. A median of 68 publications of basic, clinical, and other relevant translational science preceded successful FDA approval of first-in-class cancer drugs, with oncology-related treatments involving fewer median years of target-based research than therapies not related to cancer (33 v 43 years; P < .05). Overall, 94.4% of first-in-class drugs had at least 25 years of target-related research papers, while 85.5% of first-in-class drugs had at least 10 years of translational research publications. CONCLUSION Novel first-in-class cancer treatments are defined by diverse clinical indications, personalized molecular targets, dependence on expedited regulatory pathways, and translational research metrics reflecting this complex landscape. Biomedical informatics and AI provide scalable, data-driven ways to assess and even address important challenges in the drug development pipeline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceTranslational Research, BiomedicalUnited States Food and Drug AdministrationDrug ApprovalAntineoplastic AgentsNeoplasmsHumansUnited StatesRetrospective StudiesMedical InformaticsDrug Development

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Worldwide Medical and Safety, Pfizer Inc, New York, NY.
  • Pfizer Research and Development, Pfizer Inc, New York, NY.

ORCID-Profile: Jay G Ronquillo, Rominder Singh

Zitieren

APA

Ronquillo, J. G., South, B., Naik, P., Singh, R., De Jesus, M., Watt, S. J., & Habtezion, A. (2024). Informatics and Artificial Intelligence–Guided Assessment of the Regulatory and Translational Research Landscape of First-in-Class Oncology Drugs in the United States, 2018-2022. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00087

Vancouver

Ronquillo JG, South B, Naik P, Singh R, De Jesus M, Watt SJ, et al. Informatics and Artificial Intelligence–Guided Assessment of the Regulatory and Translational Research Landscape of First-in-Class Oncology Drugs in the United States, 2018-2022. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.24.00087

BibTeX
@article{Ronquillo2024,
  author = {Ronquillo, Jay G and South, Brett and Naik, Prakash and Singh, Rominder and De Jesus, Magdia and Watt, Stephen J and Habtezion, Aida},
  title = {Informatics and Artificial Intelligence–Guided Assessment of the Regulatory and Translational Research Landscape of First-in-Class Oncology Drugs in the United States, 2018-2022},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci.24.00087}
}
Kostenlos starten →